AIDS Therapies

Antibody 17b May Hold Key To Blocking Viral Entry

Published in AIDS Weekly, April 9th, 2001

by Michael Greer, staff medical writer - The mechanisms by which the HIV antibody 17b interferes with viral cell entry may aid in the creation of new HIV inhibitors, say researchers in Pennsylvania.

"HIV 1 utilizes CD4 and the chemokine coreceptor for viral entry," I. Chaiken and colleagues explained in the journal Biochemistry. "The coreceptor CCR5 binding site on gp120 partially overlaps with the binding epitope of 17b, a neutralizing antibody of HIV 1."

After studying the kinetic interactions between HIV proteins and cellular binding sites, Chaiken et al. found that 17b may partially block the envelope protein gp120 from both the CCR5 and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-04-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry